Replies to post #117745 on Innovation Pharmaceuticals Inc (IPIX)

[bejamin]

You are making several assumptions to support your opinion. That is a pretty susceptible way to present your opinion.

Know what you own!

[biodoc]

I agree. It's amazing that there's any impact on tumor with once a week/ 3x per month dosing for a drug with a two hour half life. Over the weekend I was taking a closer look at all the information presented so far for Kevetrin/ovarian ca and also noticed eight patients with ovarian ca on the ASCO poster. I considered the Mullerian serous adeno as possibly the ninth. It doesn't seem likely. Maybe the ovarian ca patient who dropped out was considered in the nine but not on the ASCO poster? Not sure about discontinuing after a cohort vs. dropout. Insights appreciated.

edit: iclight- just read your subsequent posts. On my way to work in a few.

[sox040713]

P21 expressions have been proven to be dose dependent. Higher dosage means higher p21 levels. Higher p21 levels mean more p53s are reactivated. We all know what healthy p53s can do.

The thymoma patient already has a 6% tumor reduction with 350/450 mg/m2 once per week. I find it hard to believe that his tumor will progress with 750 mg/m2.

The five ovarian patients with progressive disease are mostly likely from the lower cohorts. I think our focus should be on the four patients with stable disease from the higher cohorts.

Uh, no it's not. It could very easily remain stable or it could progress. Happens all the time in clinical trials.